Intracavitary treatment of malignant pleural and peritoneal effusions in cancer patients. 1994

N Gebbia, and R Mannino, and A Di Dino, and L Maxhouni, and N Bellone, and L Cinque, and A Liuzza, and P La Motta, and G Cannata, and G Gulotta
Chair of Chemotherapy, University of Palermo, Italy.

Authors present a review of the intracavitary treatment of malignant effusions in cancer patients, experience with tetracycline, mechloretamine, quinacrine, radio-isotopes, interferon beta and interferon alpha are reviewed. Personal experience with interferon alpha is reported.

UI MeSH Term Description Entries
D008466 Mechlorethamine A biologic alkylating agent that exerts its cytotoxic effects by forming DNA ADDUCTS and DNA interstrand crosslinks, thereby inhibiting rapidly proliferating cells. The hydrochloride is an antineoplastic agent used to treat HODGKIN DISEASE and LYMPHOMA. Chlorethazine,Chlormethine,Mechlorethamine Oxide,Mustine,Nitrogen Mustard,Nitrogen Mustard N-Oxide,Bis(2-chloroethyl)methylamine,Caryolysine,Cloramin,Embichin,Mechlorethamine Hydrochloride,Mechlorethamine Hydrochloride N-Oxide,Mechlorethamine N-Oxide,Methylchlorethamine,Mitomen,Mustargen,NSC-10107,NSC-762,Nitrogranulogen,Nitromin,Hydrochloride N-Oxide, Mechlorethamine,Hydrochloride, Mechlorethamine,Mechlorethamine Hydrochloride N Oxide,Mechlorethamine N Oxide,N-Oxide, Mechlorethamine Hydrochloride,N-Oxide, Nitrogen Mustard,NSC 10107,NSC 762,NSC10107,NSC762,Nitrogen Mustard N Oxide
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D010996 Pleural Effusion Presence of fluid in the pleural cavity resulting from excessive transudation or exudation from the pleural surfaces. It is a sign of disease and not a diagnosis in itself. Effusion, Pleural,Effusions, Pleural,Pleural Effusions
D011796 Quinacrine An acridine derivative formerly widely used as an antimalarial but superseded by chloroquine in recent years. It has also been used as an anthelmintic and in the treatment of giardiasis and malignant effusions. It is used in cell biological experiments as an inhibitor of phospholipase A2. Mepacrine,Acrichine,Atabrine,Atebrin,Quinacrine Dihydrochloride,Quinacrine Dihydrochloride, Dihydrate,Quinacrine Dihyrochloride, (R)-Isomer,Quinacrine Dihyrochloride, (S)-Isomer,Quinacrine Dimesylate,Quinacrine Hydrochloride,Quinacrine Monoacetate,Quinacrine Monohydrochloride,Quinacrine Monomesylate,Quinacrine, (+-)-Isomer,Quinacrine, (R)-Isomer,Quinacrine, (S)-Isomer,Dihydrochloride, Quinacrine,Dimesylate, Quinacrine,Hydrochloride, Quinacrine,Monoacetate, Quinacrine,Monohydrochloride, Quinacrine,Monomesylate, Quinacrine
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D001761 Bleomycin A complex of related glycopeptide antibiotics from Streptomyces verticillus consisting of bleomycin A2 and B2. It inhibits DNA metabolism and is used as an antineoplastic, especially for solid tumors. BLEO-cell,Blanoxan,Blenoxane,Bleolem,Bleomicina,Bleomycin A(2),Bleomycin A2,Bleomycin B(2),Bleomycin B2,Bleomycin Sulfate,Bleomycins,Bleomycinum Mack,Bléomycine Bellon,BLEO cell,BLEOcell,Bellon, Bléomycine,Mack, Bleomycinum,Sulfate, Bleomycin
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077190 Interferon alpha-2 Alpha interferon encoded by the human IFNA2 gene. Recombinant forms are used in the treatment of CHRONIC HEPATITIS B; CHRONIC HEPATITIS C; KAPOSI SARCOMA; MELANOMA; and HAIRY CELL LEUKEMIA. IFN-alpha 2,IFN-alpha-2,IFNalpha-2b, Recombinant,Interferon alfa-2a,Interferon alfa-2b,Interferon alpha-2b, Recombinant,Interferon alpha-A,Interferon-alpha 2,Intron A (Interferon),LeIF A,Reaferon,Recombinant Interferon alpha-2a,Recombinant Interferon alpha-2b,Ro 22-8181,Roferon-A,Sch-30500,Viferon,IFNalpha 2b, Recombinant,Interferon alfa 2a,Interferon alfa 2b,Interferon alpha 2,Interferon alpha 2b, Recombinant,Interferon alpha A,Interferon alpha-2a, Recombinant,Recombinant IFNalpha-2b,Recombinant Interferon alpha 2a,Recombinant Interferon alpha 2b,Ro 22 8181,Ro 228181,Roferon A,RoferonA,Sch 30500,Sch30500
D001202 Ascitic Fluid The serous fluid of ASCITES, the accumulation of fluids in the PERITONEAL CAVITY. Peritoneal Effusion,Peritoneal Fluid,Ascitic Fluids,Effusion, Peritoneal,Fluid, Ascitic,Fluid, Peritoneal,Peritoneal Effusions,Peritoneal Fluids
D013752 Tetracycline A naphthacene antibiotic that inhibits AMINO ACYL TRNA binding during protein synthesis. 4-Epitetracycline,Achromycin,Achromycin V,Hostacyclin,Sustamycin,Tetrabid,Tetracycline Hydrochloride,Tetracycline Monohydrochloride,Topicycline,4 Epitetracycline

Related Publications

N Gebbia, and R Mannino, and A Di Dino, and L Maxhouni, and N Bellone, and L Cinque, and A Liuzza, and P La Motta, and G Cannata, and G Gulotta
October 1968, Acta radiologica: therapy, physics, biology,
N Gebbia, and R Mannino, and A Di Dino, and L Maxhouni, and N Bellone, and L Cinque, and A Liuzza, and P La Motta, and G Cannata, and G Gulotta
August 1988, Cancer,
N Gebbia, and R Mannino, and A Di Dino, and L Maxhouni, and N Bellone, and L Cinque, and A Liuzza, and P La Motta, and G Cannata, and G Gulotta
January 1952, British medical bulletin,
N Gebbia, and R Mannino, and A Di Dino, and L Maxhouni, and N Bellone, and L Cinque, and A Liuzza, and P La Motta, and G Cannata, and G Gulotta
March 1982, Surgery, gynecology & obstetrics,
N Gebbia, and R Mannino, and A Di Dino, and L Maxhouni, and N Bellone, and L Cinque, and A Liuzza, and P La Motta, and G Cannata, and G Gulotta
January 1989, Journal of surgical oncology. Supplement,
N Gebbia, and R Mannino, and A Di Dino, and L Maxhouni, and N Bellone, and L Cinque, and A Liuzza, and P La Motta, and G Cannata, and G Gulotta
January 1989, Surgery annual,
N Gebbia, and R Mannino, and A Di Dino, and L Maxhouni, and N Bellone, and L Cinque, and A Liuzza, and P La Motta, and G Cannata, and G Gulotta
April 1992, Der Gynakologe,
N Gebbia, and R Mannino, and A Di Dino, and L Maxhouni, and N Bellone, and L Cinque, and A Liuzza, and P La Motta, and G Cannata, and G Gulotta
January 1983, Cancer,
N Gebbia, and R Mannino, and A Di Dino, and L Maxhouni, and N Bellone, and L Cinque, and A Liuzza, and P La Motta, and G Cannata, and G Gulotta
January 1974, Acta cytologica,
N Gebbia, and R Mannino, and A Di Dino, and L Maxhouni, and N Bellone, and L Cinque, and A Liuzza, and P La Motta, and G Cannata, and G Gulotta
April 1998, Chest,
Copied contents to your clipboard!